A biopsy revealed an FGFR2-INA fusion, and he was offered off-label pemigatinib and experienced a decrease in tumor size with ongoing disease control for 20 months (Figs. 1A, C, 2C). This evidence concerns the gene FGFR2 and neoplasm.